PD-L1 upregulation accompanied with epithelial–mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Medical Oncology"
DOI: 10.1007/s12032-020-01372-y
Abstract: Pancreatic cancer is a highly progressive malignant tumor for which there is a critical unmet need for novel therapeutic strategies. A previous study of the authors indicated that VE-821, a selective inhibitor of the ataxia-telangiectasia-mutated and… read more here.
Keywords: mutant pancreatic; inhibition; pancreatic cancer; sensitivity ... See more keywords
Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
Sign Up to like & getrecommendations! Published in 2019 at "ACS nano"
DOI: 10.1021/acsnano.8b08246
Abstract: Survival of KRAS mutant pancreatic cancer is critically dependent on reprogrammed metabolism including elevated macropinocytosis, autophagy, and lysosomal degradation of proteins. Lysosomal acidification is indispensable to protein catabolism, which makes it an exploitable metabolic target… read more here.
Keywords: mutant pancreatic; rapid drug; pancreatic cancer; drug release ... See more keywords
Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors
Sign Up to like & getrecommendations! Published in 2017 at "Nature Medicine"
DOI: 10.1038/nm.4219
Abstract: Forward genetic screens with CRISPR–Cas9 genome editing enable high-resolution detection of genetic vulnerabilities in cancer cells. We conducted genome-wide CRISPR–Cas9 screens in RNF43-mutant pancreatic ductal adenocarcinoma (PDAC) cells, which rely on Wnt signaling for proliferation.… read more here.
Keywords: rnf43 mutant; mutant pancreatic; genome wide; wide crispr ... See more keywords